HE4 is an independent prognostic marker in endometrial cancer patients. (Q50949839)

25 March 2018

title

HE4 is an independent prognostic marker in endometrial cancer patients. (English)

1 reference

25 March 2018

1 reference

Andreas Widschwendter

7

object named as

Andreas Widschwendter

1 reference

25 March 2018

Irene Mutz-Dehbalaie

1

object named as

Irene Mutz-Dehbalaie

1 reference

25 March 2018

author name string

Daniel Egle

2

1 reference

25 March 2018

Siegfried Fessler

3

1 reference

25 March 2018

Michael Hubalek

4

1 reference

25 March 2018

Heidi Fiegl

5

1 reference

25 March 2018

Christian Marth

6

1 reference

25 March 2018

language of work or name

English

0 references

publication date

21 April 2012

1 reference

25 March 2018

published in

Gynecologic Oncology

1 reference

25 March 2018

volume

126

1 reference

25 March 2018

issue

2

1 reference

25 March 2018

page(s)

186-191

1 reference

25 March 2018

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

1 reference

7 January 2021

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Two pathogenetic types of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Biologic markers in endometrial cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Serum tumour markers in gynaecological cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Prognostic significance of tumour markers in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

CA 125 may not reflect disease status in patients with uterine serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Tissue and serum CA125 expression in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

HE4 as a biomarker for ovarian and endometrial cancer management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Endometrial cancer--revisiting the importance of pelvic and para aortic lymph nodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

Prognostic significance of HE4 expression in pulmonary adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.022

10.1016/J.YGYNO.2012.04.022

7 January 2021

Identifiers

DOI

1 reference

25 March 2018

OpenCitations bibliographic resource ID

0 references

1 reference

25 March 2018